Sign up for our Weekly Checkup Newsletter
Back to News
Insights · News

MedImpact to buy VytlOne's PBM and the Gateway rebate aggregator from TowerBrook's Maxor, Oregon filing shows

MedImpact has agreed to buy VytlOne's PBM and the Gateway rebate aggregator from TowerBrook Capital Partners, according to an Oregon Health Authority filing. The price is redacted.

6 min read

MedImpact Healthcare Systems, the San Diego pharmacy benefit manager that has spent the past three years buying what the larger PBMs discard, has agreed to acquire the pharmacy benefit and rebate aggregation businesses of VytlOne, the Amarillo pharmacy services company formerly known as Maxor, from its private equity owner TowerBrook Capital Partners. The transaction became public through a notice the Oregon Health Authority accepted on November 3, 2026, numbered 100 on its Health Care Market Oversight list; the only press coverage to date, an Insurance Business report on November 3, says the parties told clients on October 26. Neither side has issued a release, and the purchase price is blacked out of the public filing.

What the filing says

Under a securities purchase agreement with Maxor Acquisition, Inc. and Maxor National Pharmacy Services LLC, MedImpact will acquire all of the equity of four entities: Gateway Health Partners, Inc. and Gateway HP Management, LLC, which provide formulary and rebate management to health plans, smaller PBMs, employers and health systems, and MNPS, LLC and MNPS Nevada, LLC, the PBM that operated as MaxorPlus and now as VytlOne, whose subsidiary MaxorPlus, Ltd. holds the Oregon PBM license. VytlOne's specialty pharmacy, 340B administration and pharmacy fulfillment businesses are not part of the sale and stay with TowerBrook.

The parties filed under the Hart-Scott-Rodino Act on October 16, 2026, with copies to the Washington and Colorado attorneys general under those states' pre-merger notification laws, and say filings in Indiana and with California's Office of Health Care Affordability will follow "as applicable." They want to close as soon as approvals allow and in any event by December 31, 2026, because PBMs load new member files ahead of January 1 plan years and a later closing "may cause delays in processing claims." Exhibit 2 describes the price only as an arm's-length negotiated valuation subject to customary adjustments.

The origin story is a vendor relationship rather than an auction. MedImpact supplies claims adjudication software to the acquired companies, and the filing says the idea of an acquisition came up during discussions about that partnership in the second quarter of 2026; no other bids were solicited. Polsinelli, Mintz and the Phoenix Law Group handled legal diligence, Berkeley Research Group data security, MJA & Associates tax and Secretariat the quality of earnings.

MedImpact's stated purpose is scale against CVS Caremark, Express Scripts and OptumRx, which the filing says manage about 80 percent of U.S. prescriptions: "Neither MedImpact nor the Acquired Companies have the scale of operations necessary to compete against these giants." The acquired companies' client base skews to hospitals and health systems, which the filing calls a small share of MedImpact's own book, and MedImpact says it will keep every customer and supplier contract and formulary in place at closing.

Size, as far as Oregon reveals it

The filing's staffing forms give the clearest public measure of the two businesses. MedImpact reports 3,020 employees, eight of them in Oregon, 838,629 Oregon residents served and almost six million Oregon prescription claims in the year to September 30, 2026; its Oregon revenue rose from $198.6 million in fiscal 2023 to $285.6 million in 2024 and $537.3 million in 2025, a period that spans the Elixir integration. The Oregon authority's own summary calls MedImpact the fifth-largest PBM in the country at about five percent of prescriptions.

VytlOne's form, covering the Maxor Acquisition reporting entity, lists 318 employees, 51 of them clinical, no Oregon staff, 3,648 Oregon residents served and 10,837 Oregon claims; the PBM has no Oregon-based clients and reaches the state only through out-of-state employers, about 2,650 of whose employees live in Oregon. The companies' financial statements are redacted. VytlOne's website says its PBM has served more than 10 million lives over 30 years, and Gateway describes itself as the largest independent rebate and formulary manager with more than 10 million covered lives; BPOC, which has held a stake in Maxor since 2014 and brought Gateway into the group, lists the company's revenue as above $1 billion, a figure that covers the whole of VytlOne including the pharmacy businesses that are not being sold.

Two companies moving in opposite directions

Maxor's PBM history runs back to 1992, when the Amarillo pharmacy chain, founded in 1926, entered benefit management and created MaxorPlus. Maxor bought Pharmaceutical Specialties, a specialty pharmacy, in December 2016, Gateway Health Partners in November 2017 and the PBM and 340B assets of American Healthcare in September 2018, according to the prior-transactions list in the filing. TowerBrook agreed to buy the company in December 2022 and closed on March 1, 2023; a co-investment vehicle for that deal raised $189.4 million in a Form D filing, but the total price was never disclosed. Under TowerBrook, Maxor combined with ProxsysRx and installed Kim Tzoumakas as chief executive in January 2025, rebranded as VytlOne in June 2025 and moved the PBM to the VytlOne name on January 1, 2026. Selling the PBM and rebate aggregator leaves TowerBrook with the pharmacy operations, 340B and specialty businesses, which is where VytlOne's recent marketing has concentrated.

MedImpact, founded and still majority owned by Frederick Howe, has been the consolidator among independent PBMs. Scope's database holds its purchase of Elixir, Rite Aid's PBM, out of that company's bankruptcy in February 2024 for about $575 million, and the filing adds Authority Rx (August 2023) and Aspen Health (November 2023) in the same period. Sav-Rx, the labor-focused PBM, closed on December 31, 2025; MHW Benefit Partners and MSL Captive Solutions, two employer stop-loss and captive businesses, followed in March 2026; and in August 2026 Ares Management was reported to be leading a $2.2 billion private credit package to finance MedImpact's purchase of Medical Card System, the Puerto Rico Medicare Advantage and commercial insurer, from Kinderhook-backed MHH Healthcare. Insurance Business counts the VytlOne deal as MedImpact's fourth significant transaction since February 2026, and it is the first since Elixir that adds a rebate aggregator rather than a PBM or an employer-benefits business.

The timing also lands in a shifting regulatory frame. The Consolidated Appropriations Act of 2026, signed in February, requires PBMs and their rebate aggregators to pass rebates through to group health plans with semiannual reporting, mostly from 2029, and more than 120 state PBM bills were introduced between October 2025 and February 2026. Oregon's own 2024 law brought PBMs under state licensure in 2025, which is why a Texas PBM with no Oregon clients was required to file at all. Independent PBMs have been pairing up in response; Abarca Health and LucyRx announced a combination in June 2026 with more than nine million members.

What to watch

Whether the price surfaces through lender disclosures or a TowerBrook announcement; Oregon's preliminary review decision, which the parties have asked to be closed without comprehensive review and which must come before their December 31 deadline if the January 1 onboarding plan is to hold; and whether Indiana or California OHCA postings follow.

Sources: Oregon Health Authority, HCMO transaction 100, MedImpact - Maxor (https://www.oregon.gov/oha/HPA/HP/Pages/100-Medimpact-Maxor.aspx), including the HCMO-1 notice (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/100-Hcmo-1.pdf), transaction summary (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/100-transaction-summary.pdf), Exhibit 2 (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/100-exhibit-2.pdf), MedImpact staffing form (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/100-medimpact-staffing.pdf) and Maxor staffing form (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/100-Maxor-staffing.pdf); Insurance Business America, November 3, 2026 (https://www.insurancebusinessmag.com/us/news/benefits/medimpact-adds-rebate-aggregator-in-latest-pbm-acquisition-595955.aspx); VytlOne company history (https://vytlone.com/about/) and rebrand release via Becker's, June 9, 2025 (https://www.beckershospitalreview.com/hospital-management-administration/maxor-rebrands-as-vytlone-to-highlight-its-innovative-full-service-pharmacy-solutions-that-drive-revenue-growth-and-better-outcomes/); Gateway Health Partners (https://gatewayhealthpartners.com/about/); BPOC portfolio page (https://www.bpoc.com/portfolio/vytlone/); TowerBrook V Maxor Co-Investment Form D (https://filingflow.app/filings/0000950142-22-003424); MedImpact Sav-Rx completion release (https://www.medimpact.com/clients/resources/press-releases/medimpact-completes-acquisition-sav-rx); MedImpact MHW and MSL release, March 12, 2026 (https://www.businesswire.com/news/home/20260312790557/en/); Managed Healthcare Executive on the Elixir sale approval (https://www.managedhealthcareexecutive.com/view/court-approves-rite-aid-s-sale-of-elixir-pbm-to-medimpact); PitchBook LCD on the Medical Card System financing, August 7, 2026 (https://pitchbook.com/news/articles/medimpact-in-talks-for-2-2b-private-credit-loan-to-support-acquisition); Mintz PBM policy update, April 22, 2026 (https://www.mintz.com/insights-center/viewpoints/2026-04-22-pbm-policy-and-legislative-update-spring-2026); MedCity News on Abarca and LucyRx, June 22, 2026 (https://medcitynews.com/2026/06/abarca-health-and-lucyrx-to-combine-to-scale-independent-pbm-model/). Transaction history from the Scope Research healthcare M&A database.